UNSPSC 51432205: Dihydralazine sulfate

This classification denotes an antihypertensive agent with the molecular formula C8H10N6.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1C2B1W91NK, chemically known as 1,4-dihydrazinophthalazine sulfate but more generally known as dihydralazine sulfate, which bears US NIH Compound Identifier 81764. European Medicines Agency schedules Dihydralazine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01702MIG.

Most nations, for tariff and trade purposes, schedule dihydralazine sulfate under HS 29339990 and SITC 51577. As of Q4 2014, DIHYDRALAZINE SULFATE remains US FDA's Preferred Term for this commodity. Dihydralazine sulfate bears US NLM identifiers UMLS ID C0011569 and NCI Concept Code C81520. SMILES: C1CCC2C(C1)C(NNC2NN)NN.OS(=O)(=O)O.

UNSPSC 51432205 Dihydralazine sulfate is a Commodity code purchasing single pharmaceutical products — in this case, a specific antihypertensive medication for emergency medical use. State and local governments buying under this code acquire individual drug line items for use in emergency services, public health programs, and multi-state cooperative purchasing consortia. The scope spans sealed-bid procurements for standardized pharmaceutical inventory, including specific unit counts, expiration requirements, delivery timelines, and warranty periods covering product defects and material replacement. Issuing bodies include city fire and rescue departments (Tampa Fire Rescue through the City of Tampa Purchasing Department), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These buyers source through both direct manufacturer relationships and authorized wholesale distributors, with contracts typically spanning one to two years plus optional renewal or extension periods.

Recent activity spans three states. The City of Tampa issued IFB 26P00188 on April 24, 2026, for advanced life support medications including epinephrine, adenosine, diltiazem, and labetalol (closing April 8, 2026; estimated value $40,000), with a Small Local Business Enterprise sheltered-market 5 percent discount and delivery within ten calendar days. The Texas HHS Commission issued RFI HHS0017013 (March 27, 2026; response deadline April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs for self-insured health plans. MMCAP, administered by Minnesota Department of Administration, posted RFP S1070000015802 (January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, requiring cGMP and DSCSA compliance, $5 million commercial general liability, and pricing through three authorized wholesalers with a two-year term plus optional extensions.